Injectable local drug delivery systems for glioblastoma: a systematic review and -analysis of progress to date

• Published in: Biomaterials science 2023-02, Vol.11 (5), p.1553-1566
• Main Authors: Wang, Yu, Bastiancich, Chiara, Newland, Ben
• Format: Article
• ISSN: 2047-4830; 2047-4849
• DOI: 10.1039/d2bm01534j

Glioblastoma (GBM) is an aggressive malignant cancer associated with bleak prognosis and high mortality. The current standard of care for GBM is maximum surgical resection plus radiotherapy and temozolomide (TMZ) chemotherapy. The blood brain barrier (BBB) remains the main obstacle for chemotherapy and severely limits the choice of therapeutic agents. Local treatment allows drugs to circumvent the BBB and reduces systemic side effects. Despite much research effort, to date, no drug delivery system (DDS) designed to be directly injected into brain tumors has been clinically approved, and a systematic overview of the progress in this field, or lack thereof, is missing. In this review, a systematic search of pre-clinical literature was conducted which resulted in 36 original articles on injectable DDS for local treatment of GBM which met the inclusion criteria. A wide range of injectable DDS have been developed and tested pre-clinically which include nanoparticles, liposomes, microspheres, hydrogels and others. meta -Analyses of the included studies showed that, overall, local administration of injectable DDS was beneficial to increase the animal's survival time. Finally, this review summarized the therapeutic effect after local treatment and discussed the shortcomings of the experimental setting in in vivo studies. This review systematically searched and screened articles researching injectable drug delivery systems (DDS) to locally treat glioblastoma in preclinical studies. The results of meta -analyses showed a survival benefit for animals treated with DDSs.